[go: up one dir, main page]

US20190216727A1 - Punctal Plug With Active Agent - Google Patents

Punctal Plug With Active Agent Download PDF

Info

Publication number
US20190216727A1
US20190216727A1 US16/360,561 US201916360561A US2019216727A1 US 20190216727 A1 US20190216727 A1 US 20190216727A1 US 201916360561 A US201916360561 A US 201916360561A US 2019216727 A1 US2019216727 A1 US 2019216727A1
Authority
US
United States
Prior art keywords
active agent
implant
plug
subject
punctal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/360,561
Other versions
US20200138701A9 (en
Inventor
Steven A. Odrich
Liane C. Glazer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mati Therapeutics Inc
Original Assignee
Mati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35096541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20190216727(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mati Therapeutics Inc filed Critical Mati Therapeutics Inc
Priority to US16/360,561 priority Critical patent/US20200138701A9/en
Publication of US20190216727A1 publication Critical patent/US20190216727A1/en
Publication of US20200138701A9 publication Critical patent/US20200138701A9/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00772—Apparatus for restoration of tear ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Definitions

  • the present invention relates generally to the field of medicine, and in particular to a new and useful method and apparatus for administering an active agent, i.e. a medicine or medication, to a subject by transdermal or other surface absorption of the agent into the tissues in and around one or both eyes of the subject.
  • an active agent i.e. a medicine or medication
  • Punctal plugs are known which are made in suitable dimensions and of suitable materials to be removably inserted into the upper and/or lower punctal apertures or punctum of the eye, to block the opening and the canaliculus communicating therewith, to prevent drainage of lacrimal fluid (tears).
  • Such plugs are known to be made of suitable materials, such as polymers, for example polytetrafluorethylene (known by the trademark TEFLON), or hydroxyethylmethacrylate (HEMA), hydrophilic polymer, methyl methacrylate, or silicon, or even of stainless steel or other inert metal material.
  • an active agent such as nicotine or a birth control drug
  • a patch which can be worn against the skin of a subject for transdermally administering the active agent to the subject.
  • an ocular implant such as a punctal plug
  • the active agent or drug is meant for treating the tissues at the walls of the canaliculus, for example, the drug is applied only to inner surfaces of the plug that are adapted to be in contact with or near the tissues of the canaliculus.
  • the presence of tears is highly advantageous as a natural vehicle or carrier for the agent.
  • the active agent or drug is meant for treating the eye itself, the drug is applied only to outer surfaces of the implant or plug that are adapted to be outside the canaliculus.
  • the presence of previously secreted tears or a tear pool is again advantageous as a natural vehicle or carrier for the agent.
  • Any or all surfaces of the implant may carry the active agent there the desire is simply to have the agent enter the subjects blood stream via the tissues in and around the eye.
  • FIG. 1 is a schematic perspective view of an ocular implant in the form of a punctal plug according to the present invention.
  • FIG. 2 is a perspective view of the area around the eye with other embodiments of the invention.
  • FIG. 1 shows a punctal plug generally designated 10 , having a stem 12 for insertion into the punctal aperture 20 of an eye 24 , and along the canaliculus 22 communicating with the aperture.
  • Plug 10 has a large stopper structure 14 connected to the outer end of stem 12 for seating against the aperture 20 and sealing the canaliculus 22 against the flow of tears onto the surface of the eye or eyeball 24 .
  • FIG. 2 illustrates an eye 24 communicating with upper and lower canaliculi 22 a and 22 b , each with their our implant 10 a and 10 b .
  • Implant 10 a is a substantially cylindrical and solid collagen plug that has been inserted into the upper punctum or tear duct 20 a , to block the flow of tears while lower implant 10 b is hollow like a straw for the passage of tears.
  • Implant 10 b includes a tapered shaft or stem 12 a with a flared open end 12 b immobilized at the lower punctum 20 b .
  • a mushroom shaped inner stopper 14 a is formed at the opposite end of shaft 12 a for further setting the location of the implant in the tear duct.
  • One of the embodiments illustrated in FIG. 2 may include a hollow core of the plug and another, e.g. the lower one, may include a hollow core filled with medication.
  • the active agent e.g. a medicine or medication is applied, e.g. in one or more bands of polymer material 16 at the inner end of the stem, or at 18 on the outer end of the stopper 14 in the embodiment of FIG. 1 , or over some or all of the surfaces of the implants of FIG. 2 , or otherwise.
  • Polymer that is absorbent to the agent is preferable so that sufficient agent is present and available for discharge into the surrounding tissues.
  • a porous or absorbent material can alternatively be used to make up the entire plug or implant which can be saturated with the active agent.
  • the hollow implant 10 b of FIG. 2 is also particularly useful in that the active agent can be applied to, or is otherwise available at the inner surface or interior of the implant, and is uniquely structured to pass tears and thus administer the active agent to the tear stream in a fashion that is controlled by the flow of tears which thus act as the carrier for the agent.
  • the hollow implant of the present invention provides a very different drug administering method, scheme and structure.
  • Non-limiting examples of the active agents or medications which are appropriate for use with the invention include, for example only: topical prostaglandin derivatives such as latanoprost, travaprost and bimataprost used for the topical treatment of glaucoma. Also a treatment for corneal infections is appropriate using ciprofloxacin, moxifloxacin or gatifloxacin.
  • Systemic medications useful for this invention are those used for hypertension such as atenolol, nifedipine or hydrochlorothiazide. Any other chronic disease requiring chronic medication could be used.
  • allergic conjunctivitis and rhinitis are also good applications for the invention, e.g. using antihistamine and anti-allergy medication such as olopatadine and cromalyn sodium in or on the implant.
  • active agents are not comprehensive in that many other agents can be used with the present invention.
  • a treatment for dry eye by topical cyclosporin is particularly interesting for administration by the present invention, but many other active agents can also be administered using the method and apparatus of the invention.
  • the invention is meant to embody all implants or devices which are implanted into the eye-lid canalicular puncta of the naso-lacrimal system with the goal of delivering drug to the eye or to the body.
  • the implant is inserted into either the inferior (lower) or superior (upper) punctum or possibly both.
  • the apparatus is constructed so as to have a drug attached to one or both sides of the implant and an occlusive plug of some inert biocompatible material.
  • the implant could be oriented in the punctal canal to deliver the drug either to the tear lake and thus the eye, or to the nasolacrimal system and thus the body's systemic circulation.
  • the drawings illustrate only three embodiments of the punctal plug or implant delivery system of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)

Abstract

A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.

Description

    FIELD AND BACKGROUND OF THE INVENTION
  • The present invention relates generally to the field of medicine, and in particular to a new and useful method and apparatus for administering an active agent, i.e. a medicine or medication, to a subject by transdermal or other surface absorption of the agent into the tissues in and around one or both eyes of the subject.
  • Punctal plugs are known which are made in suitable dimensions and of suitable materials to be removably inserted into the upper and/or lower punctal apertures or punctum of the eye, to block the opening and the canaliculus communicating therewith, to prevent drainage of lacrimal fluid (tears). Such plugs are known to be made of suitable materials, such as polymers, for example polytetrafluorethylene (known by the trademark TEFLON), or hydroxyethylmethacrylate (HEMA), hydrophilic polymer, methyl methacrylate, or silicon, or even of stainless steel or other inert metal material.
  • It is also known to apply an active agent such as nicotine or a birth control drug, to the inner surface of a patch which can be worn against the skin of a subject for transdermally administering the active agent to the subject.
    • SUMMARY OF THE INVENTION
  • It is an object of the present invention to provide a method and an apparatus for administering an active agent to a subject by applying the active agent to at least one surface of an ocular implant such as a punctal plug, and installing the implant, e.g. inserting the punctal plug into a punctal aperture of the subject.
  • If the active agent or drug is meant for treating the tissues at the walls of the canaliculus, for example, the drug is applied only to inner surfaces of the plug that are adapted to be in contact with or near the tissues of the canaliculus. The presence of tears is highly advantageous as a natural vehicle or carrier for the agent.
  • If the active agent or drug is meant for treating the eye itself, the drug is applied only to outer surfaces of the implant or plug that are adapted to be outside the canaliculus. Here the presence of previously secreted tears or a tear pool is again advantageous as a natural vehicle or carrier for the agent.
  • Any or all surfaces of the implant may carry the active agent there the desire is simply to have the agent enter the subjects blood stream via the tissues in and around the eye.
  • The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming a part of this disclosure. For a better understanding of the invention, its operating advantages and specific objects attained by its uses, reference is made to the accompanying drawings and descriptive matter in which preferred embodiments of the invention are illustrated.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • In the drawings:
  • FIG. 1 is a schematic perspective view of an ocular implant in the form of a punctal plug according to the present invention; and
  • FIG. 2 is a perspective view of the area around the eye with other embodiments of the invention.
    •  DESCRIPTION OF THE PREFERRED EMBODIMENT
  • Referring now to the drawing, FIG. 1 shows a punctal plug generally designated 10, having a stem 12 for insertion into the punctal aperture 20 of an eye 24, and along the canaliculus 22 communicating with the aperture.
  • Plug 10 has a large stopper structure 14 connected to the outer end of stem 12 for seating against the aperture 20 and sealing the canaliculus 22 against the flow of tears onto the surface of the eye or eyeball 24.
  • FIG. 2, where the same of similar numerals are used to designate functionally similar parts, illustrates an eye 24 communicating with upper and lower canaliculi 22 a and 22 b, each with their our implant 10 a and 10 b. Implant 10 a is a substantially cylindrical and solid collagen plug that has been inserted into the upper punctum or tear duct 20 a, to block the flow of tears while lower implant 10 b is hollow like a straw for the passage of tears. Implant 10 b includes a tapered shaft or stem 12 a with a flared open end 12 b immobilized at the lower punctum 20 b. A mushroom shaped inner stopper 14 a is formed at the opposite end of shaft 12 a for further setting the location of the implant in the tear duct.
  • One of the embodiments illustrated in FIG. 2, e.g. the upper implant, may include a hollow core of the plug and another, e.g. the lower one, may include a hollow core filled with medication.
  • The active agent, e.g. a medicine or medication is applied, e.g. in one or more bands of polymer material 16 at the inner end of the stem, or at 18 on the outer end of the stopper 14 in the embodiment of FIG. 1, or over some or all of the surfaces of the implants of FIG. 2, or otherwise. Polymer that is absorbent to the agent is preferable so that sufficient agent is present and available for discharge into the surrounding tissues. A porous or absorbent material can alternatively be used to make up the entire plug or implant which can be saturated with the active agent.
  • The hollow implant 10 b of FIG. 2 is also particularly useful in that the active agent can be applied to, or is otherwise available at the inner surface or interior of the implant, and is uniquely structured to pass tears and thus administer the active agent to the tear stream in a fashion that is controlled by the flow of tears which thus act as the carrier for the agent. Unlike the usual tear stopping punctal plug, the hollow implant of the present invention provides a very different drug administering method, scheme and structure.
  • Non-limiting examples of the active agents or medications which are appropriate for use with the invention include, for example only: topical prostaglandin derivatives such as latanoprost, travaprost and bimataprost used for the topical treatment of glaucoma. Also a treatment for corneal infections is appropriate using ciprofloxacin, moxifloxacin or gatifloxacin. Systemic medications useful for this invention are those used for hypertension such as atenolol, nifedipine or hydrochlorothiazide. Any other chronic disease requiring chronic medication could be used.
  • The treatment of allergic conjunctivitis and rhinitis are also good applications for the invention, e.g. using antihistamine and anti-allergy medication such as olopatadine and cromalyn sodium in or on the implant.
  • The advantage is that there would be no need for chronic pill-taking or drop taking. A once-per 3-6 month visit to the eye doctor would be all that is needed. Also the issue of non-compliance, a major impediment to successful treatment, would by avoided by the invention.
  • This list of active agents is not comprehensive in that many other agents can be used with the present invention. For example, a treatment for dry eye by topical cyclosporin is particularly interesting for administration by the present invention, but many other active agents can also be administered using the method and apparatus of the invention.
  • The invention is meant to embody all implants or devices which are implanted into the eye-lid canalicular puncta of the naso-lacrimal system with the goal of delivering drug to the eye or to the body.
  • The implant is inserted into either the inferior (lower) or superior (upper) punctum or possibly both. The apparatus is constructed so as to have a drug attached to one or both sides of the implant and an occlusive plug of some inert biocompatible material.
  • Depending on the desired therapy, the implant could be oriented in the punctal canal to deliver the drug either to the tear lake and thus the eye, or to the nasolacrimal system and thus the body's systemic circulation. The drawings illustrate only three embodiments of the punctal plug or implant delivery system of the invention.
  • While a specific embodiment of the invention has been shown and described in detail to illustrate the application of the principles of the invention, it will be understood that the invention may be embodied otherwise without departing from such principles.

Claims (19)

What is claimed is:
1. A method for administering an active agent to a subject, the active agent having been applied to at least one surface of an ocular implant, the method comprising installing the implant at the eye of the subject for administering the active agent through tissues of the eye.
2. A method according to claim 1, including the step of applying the active agent to at least one surface of the ocular implant.
3. A method according to claim 1, wherein the ocular implant is a punctal plug, the method including inserting the plug into a punctal aperture of the subject.
4. A method according to claim 1, wherein the ocular implant is a punctal plug, the method including applying the active agent to a stem of the plug and inserting the stem into a canaliculus of the subject.
5. A method according to claim 1, wherein the ocular implant is a punctal plug, the method including applying the active agent to a stopper of the plug, the plug having a stem for inserting into a punctal aperture of the subject.
6. A method according to claim 1, wherein the active agent is a medicine.
7. A method according to claim 1, wherein the active agent is selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimataprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a mediation for treating hypertension; atenolol; nifedipine; and hydrochlorothiazide.
8. A method according to claim 1, wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.
9. A method according to claim 1, wherein the implant is hollow for passing tears.
10. A method according to claim 1, wherein the implant is hollow for passing tears and the active agent is made available at an interior of the hollow implant for being carried by the passage of tears.
11. An apparatus for administering an active agent to a subject, comprising an active agent applied to at least one surface of an ocular implant for installation at the eye of the subject.
12. An apparatus according to claim 11, wherein the ocular implant is a punctal plug.
13. An apparatus according to claim 11, wherein the ocular implant is a punctal plug, the active agent being on a stem of the plug for insertion into a canaliculus of the subject.
14. An apparatus according to claim 11, wherein the ocular implant is a punctal plug, the active agent being on a stopper of the plug, the plug having a stem for insertion into a punctal aperture of the subject.
15. An apparatus according to claim 11, wherein the active agent is a medicine.
16. An apparatus according to claim 11, wherein the active agent is selected from the group comprising: topical prostaglandin; latanoprost; travaprost; bimataprost; a medication for a treatment for corneal infections; ciprofloxacin; moxifloxacin; gatifloxacin; a systemic medication; a mediation for treating hypertension; atenolol; nifedipine; and hydrochlorothiazide.
17. An apparatus according to claim 11, wherein the active agent is a medication for the topical treatment of glaucoma or corneal infection.
18. An apparatus according to claim 11, wherein the implant is hollow for passing tears.
19. An apparatus according to claim 11, wherein the implant is hollow for passing tears and the active agent is made available at an interior of the hollow implant.
US16/360,561 2004-04-15 2019-03-21 Punctal Plug With Active Agent Abandoned US20200138701A9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/360,561 US20200138701A9 (en) 2004-04-15 2019-03-21 Punctal Plug With Active Agent

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/825,047 US20050232972A1 (en) 2004-04-15 2004-04-15 Drug delivery via punctal plug
US12/604,202 US20100040670A1 (en) 2004-04-15 2009-10-22 Drug delivery via ocular implant
US13/533,676 US20120277694A1 (en) 2004-04-15 2012-06-26 Punctal plug with active agent
US14/472,844 US9463114B2 (en) 2004-04-15 2014-08-29 Punctal plug with active agent
US15/247,574 US20170056322A1 (en) 2004-04-15 2016-08-25 Punctal plug with active agent
US15/427,578 US20170172916A1 (en) 2004-04-15 2017-02-08 Punctal plug with active agent
US16/360,561 US20200138701A9 (en) 2004-04-15 2019-03-21 Punctal Plug With Active Agent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/427,578 Continuation US20170172916A1 (en) 2004-04-15 2017-02-08 Punctal plug with active agent

Publications (2)

Publication Number Publication Date
US20190216727A1 true US20190216727A1 (en) 2019-07-18
US20200138701A9 US20200138701A9 (en) 2020-05-07

Family

ID=35096541

Family Applications (7)

Application Number Title Priority Date Filing Date
US10/825,047 Abandoned US20050232972A1 (en) 2004-04-15 2004-04-15 Drug delivery via punctal plug
US12/604,202 Abandoned US20100040670A1 (en) 2004-04-15 2009-10-22 Drug delivery via ocular implant
US13/533,676 Abandoned US20120277694A1 (en) 2004-04-15 2012-06-26 Punctal plug with active agent
US14/472,844 Expired - Lifetime US9463114B2 (en) 2004-04-15 2014-08-29 Punctal plug with active agent
US15/247,574 Abandoned US20170056322A1 (en) 2004-04-15 2016-08-25 Punctal plug with active agent
US15/427,578 Abandoned US20170172916A1 (en) 2004-04-15 2017-02-08 Punctal plug with active agent
US16/360,561 Abandoned US20200138701A9 (en) 2004-04-15 2019-03-21 Punctal Plug With Active Agent

Family Applications Before (6)

Application Number Title Priority Date Filing Date
US10/825,047 Abandoned US20050232972A1 (en) 2004-04-15 2004-04-15 Drug delivery via punctal plug
US12/604,202 Abandoned US20100040670A1 (en) 2004-04-15 2009-10-22 Drug delivery via ocular implant
US13/533,676 Abandoned US20120277694A1 (en) 2004-04-15 2012-06-26 Punctal plug with active agent
US14/472,844 Expired - Lifetime US9463114B2 (en) 2004-04-15 2014-08-29 Punctal plug with active agent
US15/247,574 Abandoned US20170056322A1 (en) 2004-04-15 2016-08-25 Punctal plug with active agent
US15/427,578 Abandoned US20170172916A1 (en) 2004-04-15 2017-02-08 Punctal plug with active agent

Country Status (1)

Country Link
US (7) US20050232972A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US11622935B2 (en) 2020-02-06 2023-04-11 Ocular Therapeutix, Inc. Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles
US12144889B2 (en) 2020-04-27 2024-11-19 Ocular Therapeutix, Inc. Methods of treating allergic conjunctivitis

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20040225250A1 (en) 2003-05-05 2004-11-11 Michael Yablonski Internal shunt and method for treating glaucoma
US7291125B2 (en) 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
CA2572592C (en) 2004-07-02 2015-09-08 Eliot Lazar Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
WO2007028005A2 (en) * 2005-09-01 2007-03-08 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
JP2009523540A (en) 2006-01-17 2009-06-25 トランセンド メディカル インコーポレイテッド Glaucoma treatment equipment
WO2007084582A2 (en) 2006-01-17 2007-07-26 Forsight Labs, Llc Drug delivery treatment device
DK2004172T3 (en) * 2006-03-31 2019-04-23 Mati Therapeutics Inc PHARMACEUTICAL ADMINISTRATION STRUCTURES AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM
SG138567A1 (en) * 2006-06-21 2008-01-28 Johnson & Johnson Vision Care Punctal plugs for the delivery of active agents
US9474645B2 (en) * 2006-06-21 2016-10-25 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
CN101505694B (en) * 2006-06-21 2012-02-22 庄臣及庄臣视力保护公司 Punctal plugs for the delivery of active agents
US9173773B2 (en) * 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US20080045911A1 (en) * 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
WO2008027371A2 (en) * 2006-08-29 2008-03-06 Surmodics, Inc. Low profile bioactive agent delivery device
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
WO2008083118A1 (en) * 2006-12-26 2008-07-10 Qlt Plug Delivery, Inc. Drug delivery implants for inhibition of optical defects
UY30883A1 (en) 2007-01-31 2008-05-31 Alcon Res PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
WO2009012406A1 (en) 2007-07-17 2009-01-22 Transcend Medical, Inc. Ocular implant with hydrogel expansion capabilities reference to priority document
ES2732555T3 (en) 2007-09-07 2019-11-25 Mati Therapeutics Inc Tear implants and related methods
CA2698580C (en) * 2007-09-07 2016-10-11 Qlt Plug Delivery, Inc. Lacrimal implant detection
US20090104243A1 (en) * 2007-09-07 2009-04-23 Qlt Plug Delivery, Inc. - Qpdi Drug cores for sustained release of therapeutic agents
CN102014816B (en) * 2008-02-18 2015-04-15 马缇医疗股份有限公司 Lacrimal implants and related methods
EP2276471B1 (en) 2008-04-30 2018-08-08 Mati Therapeutics Inc. Composite lacrimal insert and related methods
US9949942B2 (en) 2008-05-09 2018-04-24 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
EP2303184A4 (en) * 2008-06-24 2013-06-19 Quadra Logic Tech Inc GLAUCOMA ASSOCIATION TREATMENT
EP3298995A1 (en) 2008-06-25 2018-03-28 Novartis AG Ocular implant with shape change capabilities
TW201006453A (en) * 2008-07-08 2010-02-16 Qlt Plug Delivery Inc Lacrimal implant body including comforting agent
US20100158980A1 (en) * 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
RU2011134043A (en) * 2009-01-23 2013-02-20 Клт Инк. DELIVERY OF ONE OR MORE AGENT WITH LONG-TERM RELEASE
WO2010088258A2 (en) 2009-01-28 2010-08-05 Transcend Medical, Inc. Ocular implant with stiffness qualities, methods of implantation and system
AU2010213612B2 (en) 2009-02-12 2015-04-30 Incept, Llc Drug delivery through hydrogel plugs
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
KR20110132369A (en) * 2009-02-23 2011-12-07 큐엘티 인코포레이티드 Tear Implants and Related Methods
TWI495459B (en) * 2009-03-31 2015-08-11 Johnson & Johnson Vision Care Punctal plugs
US9421127B2 (en) 2009-03-31 2016-08-23 Johnson & Johnson Vision Care, Inc. Punctal plugs
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP4289416A3 (en) 2009-05-18 2024-01-03 Dose Medical Corporation Drug eluting ocular implant
ES2921527T3 (en) 2009-06-03 2022-08-29 Forsight Vision5 Inc Anterior segment drug delivery
EP2503969A1 (en) 2009-11-27 2012-10-03 QLT Inc. Lacrimal implants including split and insertable drug core
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US9259352B2 (en) 2010-03-29 2016-02-16 Johnson & Johnson Vision Care, Inc. Punctal plugs
US9259351B2 (en) 2010-03-29 2016-02-16 Johnson & Johnson Vision Care, Inc. Punctal plugs
CA2798084A1 (en) 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
ES2611807T3 (en) * 2011-08-29 2017-05-10 Mati Therapeutics Inc. Administration for sustained release of active agents to treat glaucoma and ocular hypertension
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
WO2013049107A2 (en) * 2011-09-27 2013-04-04 The Regents Of The University Of Colorado, A Body Corporate Intraocular encapsulation of oxygenic bacteria
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US9241832B2 (en) 2012-04-24 2016-01-26 Transcend Medical, Inc. Delivery system for ocular implant
CA2872338C (en) * 2012-05-03 2021-09-14 Qlt Inc. Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EA030047B1 (en) 2012-09-17 2018-06-29 Новартис Аг System for implanting in an eye and method for operating the system for implanting in an eye
US9763829B2 (en) 2012-11-14 2017-09-19 Novartis Ag Flow promoting ocular implant
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
JP6655610B2 (en) 2014-05-29 2020-02-26 グローコス コーポレーション IMPLANT WITH CONTROLLED DRUG DELIVERY FUNCTION AND METHOD OF USING THE SAME
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
HK1248570A1 (en) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o stabilized pharmaceutical formulations
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3442479A1 (en) 2016-04-20 2019-02-20 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
CN110536654A (en) 2017-04-06 2019-12-03 提尔迪克斯有限公司 Ophthalmic device and its application method
TWI797136B (en) 2017-06-16 2023-04-01 美商亞斯庫拉科技公司 Thermoresponsive polymers and uses thereof
CN108295318B (en) * 2018-01-31 2021-07-06 西安泰科迈医药科技股份有限公司 Thermosensitive injectable lacrimal duct suppository and preparation method thereof
TW202202138A (en) 2020-03-25 2022-01-16 美商歐克萊製藥公司 Ocular implant containing a tyrosine kinase inhibitor
MX2023003274A (en) 2020-09-24 2023-04-12 Ocular Therapeutix Inc Sustained release biodegradalbe intracanalicular inserts comprising a hydrogel and cyclosporine.
US12161753B2 (en) 2020-09-24 2024-12-10 Ocular Therapeutix, Inc. Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent
JP2024508811A (en) 2021-02-24 2024-02-28 オキュラ セラピューティクス，インコーポレイテッド Intracanalicular depot inserter device
CA3220272A1 (en) * 2021-05-14 2022-11-17 Glaukos Corporation Materials and methods for punctal plugs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731005A (en) * 1993-08-13 1998-03-24 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6350442B2 (en) * 1999-04-13 2002-02-26 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US20050095269A1 (en) * 2003-11-04 2005-05-05 Ainpour Parviz R. Gel plug for blockage of the canaliculus

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US577319A (en) * 1897-02-16 pfeiffer
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3949750A (en) * 1974-10-07 1976-04-13 Freeman Jerre M Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4660546A (en) * 1984-11-07 1987-04-28 Robert S. Herrick Method for treating for deficiency of tears
US5053030A (en) * 1984-11-07 1991-10-01 Herrick Robert S Intracanalicular implant for horizontal canalicular blockade treatment of the eye
US5049142A (en) * 1984-11-07 1991-09-17 Herrick Robert S Intracanalicular implant for horizontal canalicular blockade treatment of the eye
US5229128A (en) * 1986-06-11 1993-07-20 Haddad Heskel M Drug delivery ophthalmic insert and method of preparing same
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4886488A (en) 1987-08-06 1989-12-12 White Thomas C Glaucoma drainage the lacrimal system and method
US4915684A (en) * 1988-06-21 1990-04-10 Mackeen Donald L Method and apparatus for modulating the flow of lacrimal fluid through a punctum and associated canaliculus
US5133159A (en) * 1989-01-13 1992-07-28 Nestle S.A. Method for polishing silicone products
US4959048A (en) * 1989-01-17 1990-09-25 Helix Medical, Inc. Lacrimal duct occluder
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5128058A (en) * 1989-05-31 1992-07-07 Hoya Corporation Contact lens cleaner containing a microcapsular polishing agent
IE910450A1 (en) 1990-02-15 1991-08-28 Bausch & Lomb Soft contact lens processing aid
US5171270A (en) 1990-03-29 1992-12-15 Herrick Robert S Canalicular implant having a collapsible flared section and method
US5163959A (en) 1990-03-29 1992-11-17 Herrick Robert S Method for treating an eye with a canalicular implant having a collapsible flared section
US5041081A (en) * 1990-05-18 1991-08-20 Odrich Ronald B Ocular implant for controlling glaucoma
US5116371A (en) * 1990-07-06 1992-05-26 Christensen James M Prosthesis with improved biocompatibility
US5096443A (en) * 1990-11-29 1992-03-17 Siemens Aktiengesellschaft Keyed apparatus for providing ground, power or signal connections
US5283063A (en) * 1992-01-31 1994-02-01 Eagle Vision Punctum plug method and apparatus
US5334137A (en) 1992-02-21 1994-08-02 Eagle Vision, Inc. Lacrimal fluid control device
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5366739A (en) * 1992-08-06 1994-11-22 Deo Corporation Method of ophthalmic drug delivery
US5469867A (en) * 1992-09-02 1995-11-28 Landec Corporation Cast-in place thermoplastic channel occluder
US5318513A (en) * 1992-09-24 1994-06-07 Leib Martin L Canalicular balloon fixation stent
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5824048A (en) * 1993-04-26 1998-10-20 Medtronic, Inc. Method for delivering a therapeutic substance to a body lumen
US5417651A (en) * 1993-07-01 1995-05-23 Guena; Nicolas Punctum plug and monocanalicular probe for lacrimal pathology
WO1995003807A1 (en) * 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US5423777A (en) * 1993-10-27 1995-06-13 Tajiri; Akira Punctum plug
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
JP3486758B2 (en) 1994-06-24 2004-01-13 株式会社高研 Injectable lacrimal canaliculus
US6149684A (en) 1995-06-07 2000-11-21 Herrick; Robert S. Punctum plug having a thin elongated lip and a distal starting tip and method of using
US5723005A (en) * 1995-06-07 1998-03-03 Herrick Family Limited Partnership Punctum plug having a collapsible flared section and method
US5766243A (en) * 1995-08-21 1998-06-16 Oasis Medical, Inc. Abrasive polished canalicular implant
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5741292A (en) * 1995-10-26 1998-04-21 Eagle Vision Punctum dilating and plug inserting instrument with push-button plug release
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5824073A (en) * 1996-03-18 1998-10-20 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
JPH1033584A (en) 1996-07-26 1998-02-10 M L C:Kk Lacrimal duct insertion appliance
US5993407A (en) 1996-10-25 1999-11-30 Moazed; Kambiz Thomas Transnasal lacrimal insert
JP2001504042A (en) * 1996-11-01 2001-03-27 アルコン ラボラトリーズ，インコーポレイテッド Low-temperature polishing method for soft acrylic articles
EP0944371A1 (en) * 1997-02-04 1999-09-29 Alain Fouere Meatus plug for lachrymal canal capable of being screwed
US6016806A (en) * 1997-03-27 2000-01-25 Eaglevision, Inc Punctum plug
US6041785A (en) 1997-03-27 2000-03-28 Eaglevision, Inc. Punctum plug
US6082362A (en) * 1997-03-27 2000-07-04 Eagle Vision, Inc. Punctum plug
US6027470A (en) * 1998-06-10 2000-02-22 Eagle Vision, Inc. Punctum plug and method for inserting the same into the punctual opening
US5961370A (en) * 1997-05-08 1999-10-05 Chiron Vision Corporation Intraocular lens tumbling process using coated beads
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US5830171A (en) 1997-08-12 1998-11-03 Odyssey Medical, Inc. Punctal occluder
US6060439A (en) * 1997-09-29 2000-05-09 Kyzen Corporation Cleaning compositions and methods for cleaning resin and polymeric materials used in manufacture
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
NL1008090C2 (en) 1998-01-22 1999-07-26 Lubberman Bernardus H M Plug for closing a tear duct.
WO1999044553A1 (en) 1998-03-02 1999-09-10 Herrick Family Limited Partnership A punctum plug having a collapsible flared section and method
US6290684B1 (en) * 1998-03-02 2001-09-18 Herrick Family Limited Partnership Punctum plug having a collapsible expanded section and distal tip extending substantially perpendicular thereto and method of inserting same
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6306114B1 (en) * 1998-06-16 2001-10-23 Eagle Vision, Inc. Valved canalicular plug for lacrimal duct occlusion
ES2159209T3 (en) 1998-07-14 2001-09-16 Alcon Lab Inc USE OF ACID 11- (3-DIMETHYLAMOPROPILIDEN) -6,11-DIHIDRODIBENZ (B, E) OXEPIN-2-ACETIC AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NON-ALBUM ADMINISTRATION OF OCULAR NEOVASCULARIZATION.
JP2000070296A (en) * 1998-08-27 2000-03-07 M L C:Kk Intra-lacrimal duct intubation appliance
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6095901A (en) * 1998-12-09 2000-08-01 Alcon Laboratories, Inc. Polishing method for soft acrylic articles
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6234175B1 (en) * 1999-03-23 2001-05-22 Medennium, Inc. Smart ocular plug design and method of insertion for punctal and intracanalicular implants
US6383192B1 (en) * 1999-04-28 2002-05-07 Mlc Limited Company Apparatus for intubation of lacrimal duct
US6428502B1 (en) * 1999-06-25 2002-08-06 Alcon Manufacturing, Ltd. Punctal cannula
US6706275B1 (en) * 1999-09-08 2004-03-16 Matthew W. Camp Scleral plug system
US6264971B1 (en) * 1999-11-04 2001-07-24 Btg International Limited Ocular insert
US7708711B2 (en) * 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US7867186B2 (en) * 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US6638239B1 (en) * 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6371122B1 (en) * 2000-06-20 2002-04-16 Robert M. Mandelkorn Gauge/dilator apparatus
US6629533B1 (en) 2000-06-30 2003-10-07 Eagle Vision, Inc. Punctum plug with at least one anchoring arm
DE60015614T2 (en) 2000-08-04 2005-11-10 Medennium, Inc., Irvine OXYGEN DEPOSIT FOR POINTS POINT AND INTRA-CHANNELAL IMPLANT
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
EP1345588A2 (en) * 2000-12-29 2003-09-24 Bausch & Lomb Incorporated Sustained release drug delivery devices
CA2432225C (en) 2001-01-03 2008-01-15 Michael J. Brubaker Sustained release drug delivery devices with prefabricated permeable plugs
WO2002058667A2 (en) 2001-01-26 2002-08-01 Bausch & Lomb Incorporated Improved process for the production of sustained release drug delivery devices
WO2002072105A2 (en) 2001-02-21 2002-09-19 Alcon, Inc. Improved prostanoid therapies for the treatment of glaucoma
CA2683224C (en) 2001-04-07 2014-12-02 Glaukos Corporation System and methods thereof for treatment of ocular disorders
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US6605108B2 (en) 2001-04-13 2003-08-12 Eagle Vision, Inc. Monocanalicular stent
DE60233217D1 (en) * 2001-05-01 2009-09-17 Corium Internat Inc HYDROGEL COMPOSITIONS
US6982090B2 (en) * 2001-05-10 2006-01-03 Gillespie Donald E More easily visualized punctum plug configurations
US7404825B2 (en) 2001-06-11 2008-07-29 Herrick Ii Robert S Implant capable of forming a differential image in an eye
US20030188879A1 (en) * 2001-08-08 2003-10-09 Easter Mark R. Self-healing cables
FR2829019B3 (en) 2001-08-31 2003-10-31 Alain Fouere LACRYMAL PLUGS AND METHODS OF FITTING THESE DEVICES
EP1424994A4 (en) 2001-09-11 2004-12-01 Smart Drug Systems Inc Preparation of sustained release pharmaceutical composition
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US6729939B2 (en) * 2001-12-17 2004-05-04 Bausch & Lomb Incorporated Polishing method for intraocular lens
FR2834446B1 (en) 2002-01-08 2004-02-13 Ioltechnologie Production EXPANDING MEATIC NAIL
US7204995B2 (en) * 2002-01-31 2007-04-17 El-Sherif Dalia M Treatment and control of dry eye by use of biodegradable polymer capsules
US20040147870A1 (en) * 2002-04-08 2004-07-29 Burns Thomas W. Glaucoma treatment kit
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US6866563B2 (en) * 2002-06-27 2005-03-15 Bausch & Lomb Incorporated Apparatus and method for target polishing intraocular lenses
FR2841770B1 (en) * 2002-07-05 2004-10-01 Ioltechnologie Production MEATIC NAIL FOR SHUTTERING A LACRYMAL MEAT
FR2844182B1 (en) 2002-09-11 2004-12-03 Humanoptics Ag CLOSURE PLUG OF A LACRYMAL CANALICLE
US7169163B2 (en) * 2002-09-30 2007-01-30 Bruce Becker Transnasal method and catheter for lacrimal system
CA2511217A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
CA2513443A1 (en) * 2003-02-26 2004-09-10 Medivas, Llc Bioactive stents and methods for use thereof
US20050283109A1 (en) 2003-03-07 2005-12-22 Peyman Gholam A Method and apparatus for lacrimal canal obstruction
US8021680B2 (en) * 2003-05-02 2011-09-20 Surmodics, Inc. Controlled release bioactive agent delivery device
US7204253B2 (en) 2003-05-22 2007-04-17 Clarity Corporation Punctum plug
US7017580B2 (en) * 2003-05-22 2006-03-28 Clarity Corporation Punctum plug system including a punctum plug and passive insertion tool therefor
JP4104137B2 (en) * 2003-05-30 2008-06-18 有限会社エム・エル・シー Punctum plug
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
JP4339635B2 (en) 2003-06-12 2009-10-07 有限会社エム・エル・シー Punctum plug
US6994684B2 (en) * 2003-06-16 2006-02-07 Alphamed Inc. Punctum plugs having fluid collecting recesses and methods of punctal occlusion
US20040265356A1 (en) 2003-06-30 2004-12-30 Bausch & Lomb Incorporated Drug delivery device
JP4280128B2 (en) 2003-08-19 2009-06-17 有限会社エム・エル・シー Punctum plug
JP2005110765A (en) 2003-10-03 2005-04-28 M L C:Kk Lacrimal punctum plug set
JP2005110930A (en) 2003-10-07 2005-04-28 M L C:Kk Lacrimal punctum plug set
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20050220882A1 (en) 2004-03-04 2005-10-06 Wilson Pritchard Materials for medical implants and occlusive devices
US20050197614A1 (en) * 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
JP2004202276A (en) 2004-04-16 2004-07-22 M L C:Kk Intubator implement for reconstructing lacrimal passage
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
JP2005312835A (en) 2004-04-30 2005-11-10 M L C:Kk Lacrimal passage stent reinforced by thread
JP4644438B2 (en) 2004-05-11 2011-03-02 有限会社エム・エル・シー Brim lacrimal stent
JP4510511B2 (en) 2004-05-18 2010-07-28 有限会社エム・エル・シー A lacrimal stent and lacrimal plug with reinforced collars
CA2572592C (en) 2004-07-02 2015-09-08 Eliot Lazar Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US20060020253A1 (en) * 2004-07-26 2006-01-26 Prescott Anthony D Implantable device having reservoir with controlled release of medication and method of manufacturing the same
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
DE102004040736B4 (en) * 2004-08-23 2007-01-11 Sanofi-Aventis Deutschland Gmbh Process for the preparation of Diarylcycloalkylderivaten
US20080038317A1 (en) * 2004-09-10 2008-02-14 Chin-Ming Chang Therapeutic Lacrimal Canalicular Inserts And Related Methods
US20060074370A1 (en) * 2004-09-24 2006-04-06 Medennium, Inc. Ocular occluder and method of insertion
AU2005309854A1 (en) 2004-11-24 2006-06-01 Therakine Ltd. An implant for intraocular drug delivery
US20060233858A1 (en) 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
US7862532B2 (en) * 2005-10-07 2011-01-04 Delta Life Sciences, Inc. Punctum plugs having insertion guides and strengthening beams
US20070132125A1 (en) * 2005-12-08 2007-06-14 Bausch & Lomb Incorporated Use of a super-cooled fluid in lens processing
JP4078371B2 (en) 2006-01-27 2008-04-23 章弘 小栗 Punctum plug
DK2004172T3 (en) 2006-03-31 2019-04-23 Mati Therapeutics Inc PHARMACEUTICAL ADMINISTRATION STRUCTURES AND COMPOSITIONS FOR NASOLACRIMAL SYSTEM
US9173773B2 (en) 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US9474645B2 (en) 2006-06-21 2016-10-25 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US20080045911A1 (en) * 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
FR2908042B1 (en) 2006-11-08 2009-06-05 Bruno Fayet MONOCANALICULONASAL AND / OR MONOCANALICULAR INTUBATION ASSEMBLY, IN PARTICULAR FOR LACRYMONASAL IMPERFORATION.
UY30883A1 (en) 2007-01-31 2008-05-31 Alcon Res PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS
ES2732555T3 (en) * 2007-09-07 2019-11-25 Mati Therapeutics Inc Tear implants and related methods
KR20100058620A (en) * 2007-09-07 2010-06-03 큐엘티 플러그 딜리버리, 인코포레이티드 Insertion and extraction tools for lacrimal implants
US20090104243A1 (en) * 2007-09-07 2009-04-23 Qlt Plug Delivery, Inc. - Qpdi Drug cores for sustained release of therapeutic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731005A (en) * 1993-08-13 1998-03-24 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
US6350442B2 (en) * 1999-04-13 2002-02-26 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20050095269A1 (en) * 2003-11-04 2005-05-05 Ainpour Parviz R. Gel plug for blockage of the canaliculus

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US12150896B2 (en) 2015-10-08 2024-11-26 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US12310890B2 (en) 2015-10-08 2025-05-27 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
US11622935B2 (en) 2020-02-06 2023-04-11 Ocular Therapeutix, Inc. Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles
US12329853B2 (en) 2020-02-06 2025-06-17 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
US12144889B2 (en) 2020-04-27 2024-11-19 Ocular Therapeutix, Inc. Methods of treating allergic conjunctivitis

Also Published As

Publication number Publication date
US20170056322A1 (en) 2017-03-02
US20120277694A1 (en) 2012-11-01
US9463114B2 (en) 2016-10-11
US20200138701A9 (en) 2020-05-07
US20100040670A1 (en) 2010-02-18
US20170172916A1 (en) 2017-06-22
US20150132358A1 (en) 2015-05-14
US20050232972A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
US20190216727A1 (en) Punctal Plug With Active Agent
US7943162B2 (en) Drug delivery device
JP4837861B2 (en) Drug delivery formulation
AU2002319606B2 (en) Ophthalmic drug delivery device
Rathore et al. An insight into ophthalmic drug delivery system
US7094226B2 (en) Ophthalmic drug delivery device
US8469934B2 (en) Pulsatile peri-corneal drug delivery device
US20070077270A1 (en) Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear
CA2586430A1 (en) Shunt for the treatment of glaucoma
HK1072177B (en) Drug delivery device

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION